a511h
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
Exhibit
Number
|
Description
|
99.1
|
20
March 2024 - Final prospectus supplement filed with the
SEC
|
99.1
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF
SUCH JURISDICTION
Haleon plc: Final prospectus supplement filed with the
SEC
20 March 2024: On
19 March 2024, Haleon plc ("Haleon") filed with the United States
Securities and Exchange Commission (the "SEC") a final prospectus
supplement to the shelf registration statement on Form
F-3 filed
by Haleon on 3 July 2023. The preliminary prospectus supplement has
been submitted to the National Storage Mechanism and is available
on the SEC's website at https://www.sec.gov/Archives/edgar/data/1900304/000110465924036189/tm248861-4_424b1.htm.
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
securities in any state or other jurisdiction in which, or to any
person to whom, such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or other jurisdiction. The
distribution or communication of this announcement or the
prospectus supplement in certain jurisdictions may be restricted by
law. Any offer may be withdrawn or revoked, without obligation or
commitment of any kind, at any time prior to notice of its
acceptance given after the effective date.
Enquiries
|
|
Investors
|
Media
|
Sonya
Ghobrial
|
+44
7392 784784
|
Zoë Bird
|
+44
7736 746167
|
Rakesh
Patel
|
+44
7552 484646
|
Nidaa
Lone
|
+44
7841 400607
|
Emma
White
|
+44
7792 750133
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
The person responsible for arranging the release of this
announcement on behalf of Haleon is Amanda Mellor, Company
Secretary.
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health,
with a purpose to deliver better everyday health with humanity.
Haleon's product portfolio spans five major categories - Oral
Health, Pain Relief, Respiratory Health, Digestive Health and
Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren,
Theraflu, Otrivin, Polident, parodontax and Centrum - are built on
trusted science, innovation and deep human
understanding.
For more information, please visit www.haleon.com.
In the United Kingdom, this announcement and its contents are
directed only at (A) "qualified investors" within the meaning of
Article 2(e) of Regulation (EU) 2017/1129 (as amended) as it forms
part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018; and (B) (i) persons who have professional
experience in matters relating to investments falling within
Article 19 of the UK Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order"), or (ii) high net
worth entities and other persons to whom it can otherwise lawfully
be communicated falling within Article 49(2)(a) to (d) of the
Order, all such persons in (A) and (B) together being referred to
as "relevant persons". This announcement must not be acted on or
relied on in the United Kingdom by persons who are not relevant
persons. Any investment activity to which this announcement relates
is available in the United Kingdom only to relevant persons and
will be engaged in only with relevant persons.
In the European Economic Area (the "EEA"), this announcement is
addressed only to and directed only at, persons in member states
who are "qualified investors" within the meaning of Article 2(e) of
Regulation (EU) 2017/1129 (as amended) ("Qualified Investors").
This announcement must not be acted on or relied on in the EEA by
persons who are not Qualified Investors. Any investment activity to
which this announcement relates is available in the EEA only to
Qualified Investors and will be engaged in only with Qualified
Investors.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
HALEON PLC
(Registrant)
|
Date:
March 20, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
Name:
|
Amanda
Mellor
|
|
|
Title:
|
Company
Secretary
|